GlassScriptPhysician profile
Kenneth R Beck
NPI 1326017484
$1,222.62
in general payments reported to CMS, 2019-2025
8 companies · $799 in 2025
The $799 reported for 2025 was more than what 88% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.56 · 2022: $91.23 · 2023: $83.22 · 2024: $228 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590 · Consulting Fee: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.83 |
| Consulting Fee | $520.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $595.30 | 2023-2025 | Truqap, Lynparza |
| Myriad Genetic Laboratories, INC. | $160.35 | 2021-2025 | Prolaris |
| Astellas Pharma US INC | $145.58 | 2025 | Xtandi |
| Tempus Ai, INC | $118.16 | 2024 | |
| Boston Scientific Corporation | $75.96 | 2022 | |
| Beckman Coulter, INC. | $59.38 | 2023-2024 | Au, Unicel Dxi Access |
| Janssen Biotech, INC. | $43.87 | 2025 | Erleada |
| Immunitybio, INC. | $24.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.